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Background: Laboratory studies and a single case–control study have suggested a protective effect of statins on the risk of
glioma. We wished to investigate the influence of statin use on the risk of glioma in a population-based setting.
Methods: We conducted a nationwide case–control study in Denmark based on population-based medical registries. We
identified all patients aged 20 to 85 years with a first diagnosis of histologically verified glioma during 2000–2009. These cases
were matched on birth year and sex with population controls. Prior use of statins since 1995 was classified into short-term use (o5
years) and long-term use (5þ years). We used conditional logistic regression to compute odds ratios (ORs), with 95% confidence
intervals (CIs), for glioma associated with statin use, adjusted for potential confounders.
Results: A total of 2656 cases and 18 480 controls were included in the study. The risk of glioma was reduced among long-term
statin users (OR¼ 0.76; 95% CI: 0.59–0.98) compared with never users of statins, and was inversely related to the intensity of statin
treatment among users (OR¼ 0.71; 95% CI: 0.44–1.15 for highest intensity). The inverse association between long-term statin
treatment and glioma risk was more pronounced among men agedp60 years (OR¼ 0.40; 95% CI: 0.17–0.91) compared with men
aged 60þ years (OR¼ 0.71; 95% CI: 0.49–1.03). An inverse association was also observed among women aged p60 years
(OR¼ 0.28; 95% CI: 0.06–1.25), but not among women over age 60 years (OR¼ 1.23; 95% CI: 0.82–1.85).
Conclusion: Long-term statin use may reduce the risk of glioma.
Given the widespread and rapidly increasing use of statins, any
association with cancer development or progression would have a
substantial impact on public health. At present, statins cannot be
recommended for primary cancer prevention or therapy because of
conflicting evidence (Boudreau et al, 2010).
However, preclinical findings of antineoplastic activity of statins
warrant their further evaluation as potential chemopreventive
agents (Chan et al, 2003; Sassano and Platania, 2008; Tapia-Pe´rez
et al, 2010). One line of investigation deserving particular attention
is the effect of statins on gliomas, a group of central nervous system
tumours of largely unknown aetiology. The most common
histological subtype, glioblastoma multiforme, accounts for more
than 50% of gliomas, and has an incidence rate of 3.5 per 1 00 000
person-years in Nordic countries and male predominance (Lo¨nn
et al, 2004).
Laboratory studies of human glioma cell lines indicate that
statins may exert antitumour activity through such mechanisms as
inhibition of cellular proliferation, growth, migration, and by
induction of apoptosis (Jones et al, 1994; Soma et al, 1994; Bouterfa
et al, 2000; Obara et al, 2002; Gliemroth et al, 2003; Jiang et al,
2004; Chan et al, 2008; Wu et al, 2009; Yanae et al, 2011). In a
phase I/II study of 18 patients with malignant gliomas, lovastatin
with and without radiotherapy was well tolerated, but had minimal
effect on tumour progression (Larner et al, 1998). To date, only one
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case–control study has addressed the risk of glioma among statin
users (Ferris et al, 2012). This study reported that X6 months of
simvastatin use was inversely associated with glioma risk (odds
ratio (OR)¼ 0.72; 95% confidence interval (CI): 0.52–1.00). Recall
bias was a potential shortcoming of this interview-based study,
with information collected from proxies in B19% of cases.
We therefore conducted a nationwide population-based case–
control study utilising registry data to further investigate the
association between statin use and glioma risk.
MATERIALS AND METHODS
We conducted a nested case–control study based on information
from population-based Danish registries: the Danish Cancer
Registry (DCR) (Storm et al, 1997; Gjerstorff, 2011), the Danish
Civil Registration System (Pedersen, 2011), the Danish National
Prescription Registry (Kildemoes et al, 2011), the Danish National
Patient Register (DNPR) (Lynge et al, 2011), and Statistics
Denmark. Unambiguous linkage between the registries was
possible using the civil registration number assigned to all Danish
residents since 1968, at birth or upon immigration to the country
(Pedersen, 2011). Danish citizens, who are mainly Caucasians, have
equal tax-supported access to health care provided by the Danish
National Health Service.
Case ascertainment. The DCR has recorded incident cases of
cancer on a nationwide basis since 1943 and has been shown to
have an almost complete ascertainment of cancer cases (Storm
et al, 1997; Gjerstorff, 2011). Reporting of gliomas to the DCR is
mandatory for all levels of malignancy. Cancer diagnoses in the
DCR are recorded according to the International Classification
of Diseases, version 10 (ICD-10), and the ICD for Oncology
(ICD-O-3) for topography and morphology codes.
Eligible cases were individuals with a first diagnosis of cranial or
spinal glioma irrespective of level of malignancy, and no prior
cancer diagnoses (except nonmelanoma skin cancer) in the DCR
during the period from 1 January 2000 to 31 December 2009. A
diagnosis of glioma was determined on the basis of ICD-10
diagnoses (see Appendix Table A1 for codes) that were
histologically confirmed, that is, with morphology codes (ICD-O-
3; see Appendix Table A1). We further classified cases by glioma
subtype, that is, glioblastoma multiforme (see Appendix Table A1),
astrocytoma grades II and III, oligodendroglioma grades II and III,
and ‘other’. The date of diagnosis recorded in the DCR was defined
as the index date. We restricted the cases to individuals aged 20 to
85 years at diagnosis.
Selection of population controls. For each case, eight controls
matched on birth year and sex were selected from the total Danish
population through the Civil Registration System (Pedersen, 2011)
using risk-set sampling (Rothman et al, 2008); that is, the controls
had to be alive and at risk for a first diagnosis of cancer (except
nonmelanoma skin cancer) at the time the corresponding case was
diagnosed (index date). The Civil Registration System is con-
tinuously updated and includes information on vital status and
migration. We used this information to restrict cases and controls
to individuals who had resided in Denmark for at least 10
consecutive years before the index date. As the latter restriction
was imposed after sampling of controls, the final ratio of cases to
controls deviated slightly from 1 : 8.
Statin exposure. Information on use of statins and other drugs
was obtained from the National Prescription Registry, which contains
information on all prescriptions dispensed at community pharmacies
in Denmark since 1995 (Kildemoes et al, 2011). For each prescription,
the Prescription Registry records date and a full description of the
dispensed product, including the anatomical therapeutic code (ATC)
(WHO, 2010) and the total number of defined daily doses (DDDs). A
DDD, established by a group of experts, represents the typical daily
dose required by an adult when the drug is used for its main indication
(WHO, 2010). Drugs used for the same indication are in principle
equipotent when measured in DDD.
We retrieved all information available from the Prescription
Registry from 1995 to the index date for both cases and controls.
Based on the number of statin prescriptions dispensed during the
period from 1995 up to 1 year before the index date, study subjects
were classified as statin ever users (X2 prescriptions recorded under
ATC codes C10AA) and statin never users (no prescriptions for
statins). Subjects with a single statin prescription were not included in
the main analyses. The risk of a ‘reverse causation’ bias (Csizmadl
et al, 2007, pp 791–810) is inherent to the study, as the first symptoms
of glioma in some cases might be interpreted as a manifestation of
cerebrovascular disease and result in the patient being prescribed a
statin. At a later stage, it becomes evident that the patient has a
tumour. Such a scenario would create a spurious excess of cancer
diagnoses after statin initiation or would mask a possible genuine
preventive effect. To minimise this potential bias, we disregarded
statin prescriptions dispensed within 1 year before the index date.
Duration of statin use was defined as the time period between
the first and last redeemed statin prescription and classified as
short duration (1–5 years before index date) or long duration (5þ
years before index date). We defined intensity of statin use as the
cumulative number of DDDs of statins prescribed to a study
subject divided by the number of days between the first and last
eligible statin prescription plus 60 days. Using tertiles of intensity
of statin use among controls as cutoff values, we classified intensity
of use as low (lower tertile), medium (middle tertile), and high
(upper tertile). In subanalyses, we classified statins as lipophilic
(simvastatin, lovastatin, fluvastatin, atorvastatin, and cerivastatin)
and hydrophilic (pravastatin and rosuvastatin).
Potential confounders. As a marker of socioeconomic status, we
used the highest educational level achieved by subjects according to
annually updated information from Statistics Denmark (Jensen
and Rasmussen, 2011). We divided study subjects into three
categories according to the number of years of schooling (7–10,
11–12, and 13þ years).
Patients suffering from a stroke are frequently prescribed statins
and undergo neuroimaging. The latter might in some instances
coincidentally reveal gliomas. We therefore regarded a history of
stroke as a potential confounder. We defined subjects as having a
history of stroke if they were recorded with ICD codes compatible
with this diagnosis (see Appendix Table A1 for codes) in the
DNPR, which contains data on all admissions to nonpsychiatric
hospitals in Denmark since 1977 and on all outpatient contacts
since 1995, including patients’ civil registration number, date of
admission/contact, and diagnosis codes.
Because diabetes is under intense scrutiny for its possible
association with cancer (Carstensen et al, 2012) and is associated
with statin use, we classified study subjects as diabetics if they had a
history of diabetes mellitus according to the DNRP (Lynge et al,
2011) or had redeemed prescriptions for antidiabetic drugs before
the index date (see Appendix Table A1 for codes). We also
considered use of certain drugs previously reported to modify the
risk of some cancers. Study subjects were classified as ever users of
the following individual compounds if they had redeemed two or
more prescriptions one or more years before the index date:
hormone replacement therapy (HRT), low-dose aspirin, selective
Cox-2 inhibitors, and other non-aspirin (NA)-NSAIDs (see
Appendix Table A1 for codes).
We used parity as a proxy measure for exposure to endogenous
sex hormones in women, as these may influence their glioma risk
(Fisher et al, 2007). We calculated parity as of the index date for
female cases and controls based on information available in the
BRITISH JOURNAL OF CANCER Use of statins and risk of glioma risk
716 www.bjcancer.com |DOI:10.1038/bjc.2012.536
nationwide Fertility Database maintained by Statistics Denmark
(Blenstrup and Knudsen, 2011). The women were classified into
the following categories according to the number of live births: 0
(nullipara), 1, 2, 3þ , or ‘missing information’.
Statistical analysis. We used conditional logistic regression to
compute adjusted ORs (and 95% CI) for glioma associated with
statin use, adjusting for age (birth year), sex, and time period (year
of index date) and for potential confounders (years of schooling,
diabetes, stroke, and use of aspirin, selective Cox2 inhibitors, and
NA-NSAIDs). We tested the effect of intensity of statin treatment
for trend. To explore potential effect measure modification, we
performed analyses stratified by age (dichotomised according to
median age of controls, i.e., o60 vs X60 years) and gender.
Information on HRT use and parity was included only in models
restricted to female study subjects used in sensitivity analyses. All
analyses were performed using Stata SE 12.1 (StataCorp, College
Station, TX, USA). The study was approved by the Danish Data
Protection Agency and the Danish Medicinal Agency.
RESULTS
Our study population comprised 2656 cases and 18 480 controls.
Of these, 1586 cases (59.7%) and 11 430 controls (61.9%) were
male. Cases and controls were also similar with regard to the
distribution of age, parity, years of schooling, prevalence of
diabetes, and use of aspirin, selective Cox2 inhibitors, NA-NSAIDs,
and HRT, but not stroke (Table 1). Among subjects treated with
statins (X2 prescriptions), the median (interquartile range (IQR))
dose was 724 DDD (IQR: 387–1262 DDD) in cases and 720 DDD
(IQR, 372–1391 DDD) in controls, and the median duration of
treatment was 2.4 years (IQR, 1.1–4.7 years) in cases and 2.8 years
(IQR, 1.2–5.2 years) in controls (excluding prescriptions dispensed
during the year before the index date).
Long-term statin use was associated with a reduced risk of
glioma (OR¼ 0.76; 95% CI: 0.59–0.98; Table 2) and was inversely
related to treatment intensity (high-intensity treatment: OR¼ 0.71;
95% CI: 0.44–1.15; P-value for trend: 0.041; Table 3). The effect of
long-term high-intensity use was restricted to lipophilic statins
(OR¼ 0.69; 95% CI: 0.38–1.25). The corresponding risk estimate
for hydrophilic statins exceeded unity (OR¼ 1.45; 95% CI: 0.31–
6.69), although based on small numbers. Reduction in glioma risk
varied across age and gender strata (Table 4). Risk of glioma
among long-term statin users was OR¼ 0.37 (95% CI: 0.18–0.75)
among subjects under age 60 years as compared with OR¼ 0.91
(95% CI: 0.69–1.19) among subjects aged 60þ years. Long-term
statin use was inversely related with the risk of glioma among men
(OR¼ 0.61; 95% CI: 0.44–0.86), but not among women
(OR¼ 1.01; 95% CI: 0.69–1.49; Table 4). However, among female
long-term statin users under age 60 years, the risk of glioma was
OR¼ 0.28 (95% CI: 0.06–1.25). Among men, the risk reduction
was also more pronounced among those under age 60 years
(OR¼ 0.40; 95% CI: 0.17–0.91), but was also substantial among
men aged 60þ years (OR¼ 0.71; 95% CI: 0.49–1.03). Ever use of
statins reduced the risk of glioblastoma multiforme (OR¼ 0.90;
95% CI: 0.73–1.12), the most frequent type of glioma (57.9% of
cases; Supplementary eTable 1). The risk reduction for glioblas-
toma multiforme was more pronounced among long-term statin
users (OR¼ 0.79; 95% CI: 0.59–1.06), in particular among subjects
with high intensity statin use (OR¼ 0.67; 95% CI: 0.37–1.20).
We performed a number of sensitivity analyses. We first
repeated all analyses including those with one prescription only in
the non-use reference group, then with long-term use defined as
7þ years of statin use, and lastly excluding NSAIDs as a covariate.
Analyses with women in separate strata were repeated with HRT
and parity included as confounder variables. The results of the
sensitivity analyses were very similar to those of the main analyses
(data not presented).
Table 1. Characteristics of study subjects in a nationwide case–control
study of glioma in Denmark, 2000–2009
Characteristic
Cases
(N¼2656)
Controls
(N¼18480)
Gender
Female 1070 (40.3) 7050 (38.2)
Male 1586 (59.7) 11 430 (61.9)
Age, years
20–29 119 (4.5) 789 (4.3)
30–39 215 (8.1) 1485 (8.0)
40–49 421 (15.9) 3019 (16.3)
50–59 681 (25.6) 4905 (26.5)
60–69 731 (27.5) 5094 (27. 6)
70–79 426 (16.0) 2805 (15.2)
80–85 63 (2.4) 383 (2.1)
Parity, number of childrena,b
0 97 (9.1) 652 (9.3)
1 165 (15.4) 1100 (15. 6)
2 418 (39.1) 2686 (38.1)
3þ 235 (22.0) 1624 (23.0)
Missing 155 (14.5) 988 (14.0)
Schooling, number of years
7–10 940 (35.4) 6395 (34.6)
11–12 1086 (40.9) 7608 (41.2)
13þ 587 (22.1) 4117 (22.3)
Missing 43 (1.6) 360 (2.0)
Diabetes 105 (4.0) 838 (4.5)
Stroke 313 (11.8) 463 (2.5)
Drug use
Statins 214 (8.1) 1601 (8.7)
Aspirin, low dose 251 (9.5) 1900 (10.3)
Selective Cox2 inhibitors 82 (3.1) 489 (2.7)
NA-NSAIDsc 1047 (39.4) 7263 (39.3)
Hormone replacement
therapya
290 (27.1) 2070 (29.4)
Abbreviations: Cox-2¼ cyclooxygenase 2; NA-NSAIDs¼non-aspirin-nonsteroidal anti-
inflammatory drugs.
aWomen only.
bData incomplete for women born before 1945. No data available on births in 2009.
cNA-NSAIDs other than Cox2 inhibitors.
Shown are numbers (percentages).
Table 2. Ever use of statins and risk of glioma
Use of
statin
Cases Controls
Crude OR
(95% CI)
Adjusted ORa
(95% CI)
Never 2442 16 879 1 (ref.) 1 (ref.)
Ever 214 1601 0.89 (0.76–1.05) 0.88 (0.73–1.05)
o5 years 118 770 1.02 (0.83–1.26) 0.96 (0.76–1.20)
5þ years 96 831 0.77 (0.61–0.96) 0.76 (0.59–0.98)
Abbreviations: CI¼ confidence interval; OR¼odds ratio; ref.¼ reference.
aAdjusted for years of schooling, diabetes, stroke, and use of aspirin, selective
cyclooxygenase 2 (Cox2) inhibitors, and non-aspirin-nonsteroidal anti-inflammatory drugs
(NA-NSAIDs).
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DISCUSSION
We found that long-term use of statins was associated with a
reduced risk of glioma. Although based on limited statistical
precision, the potential chemopreventive effect was limited to users
of lipophilic statins. This may be explained by the physiological
properties of lipophilic statins, that is, their better ability to cross
the blood–brain barrier compared with hydrophilic statins
(Botti et al, 1991; Vuletic et al, 2006). Furthermore, the effect of
long-term statin use may be more pronounced among men and,
for both genders, among those o60 years of age. We found it
particularly intriguing that the point estimates for our main
findings remained unchanged when we limited to cases with
histologically verified glioblastoma multiforme, the most aggressive
form of glioma, with only 3.3% of patients surviving for 5 years
(Bondy et al, 2008).
In the only other epidemiological study that has addressed the
relation between statin use and glioma risk, a case–control study
conducted in the United States, statin use among 458 cases was
compared with that among 353 controls (Ferris et al, 2012). Statin
use for X6 months was associated with a reduced risk of glioma
(OR¼ 0.72; 95% CI: 0.52–1.00) and the risk was further reduced in
subjects with a long treatment duration (4120 months of use,
OR¼ 0.44; 95% CI: 0.15–0.97). The OR of glioma associated with
statin use was 0.59 (95% CI: 0.38–0.92) among men and 0.85 (95%
CI: 0.51–1.43) among women. Our findings are compatible with
this study, including the gender difference in the risk estimates for
glioma, although direct comparisons between the two studies are
hampered by differences in design and setting.
Our study has a number of strengths. Our study was performed
in a setting with free access to health services independent of
income. We used nationwide registries with complete coverage and
continuously collected data on all Danish residents. Our approach
thus eliminated recall bias and minimised selection bias. The DCR
enabled us to identify incident cases of glioma and cancer-free
controls with minimal misclassification. We also restricted our
sample to histologically verified cases, which enhanced case validity
and allowed us to perform analyses on subtypes of glioma. Our
study also has some potential weaknesses that should be
considered. Because the National Prescription Registry has
collected nationwide data only since 1995, the medication histories
of our subjects spanned 5 to 15 years, depending on their index
dates. This left-truncation of Prescription Registry data may give
rise to two potential problems. First, subjects who stopped using
statins before 1995 were misclassified as never users in our study.
Second, the duration of current use may be underestimated in
subjects with statin use before 1995. However, such misclassifica-
tions most likely would produce a conservative misclassification
bias, that is, reduce the association between statin use and glioma
risk. Furthermore, as statins were only used sparsely in Denmark
before the publication of the Scandinavian Simvastatin Survival
Study (4S) (Scandinavian Simvastatin Survival Study Group, 1994)
in 1994 (Riahi et al, 2001), we believe that such misclassification is
minor. Our study was also limited by our inability to evaluate
compliance with statin prescriptions; however, a drug utilisation
study of statin use in the Danish population indicates that degree
of statin persistence is high (Larsen et al, 2002).
It is conceivable that before their detection, brain tumours could
exert influences on adherence to medication use, for example, by
influencing cognitive skills. By ignoring the use of statins in the
year before the index date, we believe that we have severely reduced
the impact of such effects, particularly in our analyses restricted to
cases of glioblastoma multiforme, a glioma subtype with well-
established rapid development.
Exposure to ionising radiation is the only established environ-
mental cause of glioma (Fisher et al, 2007; Bondy et al, 2008).
Although we were not able to adjust for this covariate, the
attributable risk proportion of radiation is small and unlikely to be
associated with statin use. More importantly, we only included
study subjects with an initial primary cancer, so that individuals
with previous cancers who may have been exposed to ionising
radiation were excluded by design. As well, lifestyle factors
indirectly could influence our study findings if such factors were
both related to the likelihood of being prescribed statins and risk of
glioma. According to a recent Danish study linking prescription
data on statin use to data from a survey of 13 996 subjects
(including 1641 current statin users), there was no indication of a
particularly healthy lifestyle associated with statin use (Thomsen
et al, 2011). However, another Danish study based primarily on
statin use in the initial years following the launch of these drugs
showed a clear socioeconomic gradient in statin use among men
but not women (Thomsen et al, 2005). Another concern is that we
only accounted for highest achieved level of schooling, which may
have resulted in residual confounding of socioeconomic indicators.
Importantly, however, a Danish study based on DCR data found
no association between incidence of central nervous system
tumours and socioeconomic status (Schmidt et al, 2008).
Table 3. Duration and intensity of statin use and glioma risk
Statin use Cases Controls Crude odds ratio (95% confidence interval (CI))
Adjusted odds ratioa
(95% CI)
Never use 2442 16 879 1 (reference) 1 (reference)
Short-term useb,c
Low intensity 24 179 0.87 (0.57–1.34) 0.94 (0.60–1.47)
Medium intensity 41 250 1.11 (0.79–1.57) 1.10 (0.77–1.56)
High intensity 53 341 1.04 (0.77–1.41) 1.01 (0.73–1.39)
Long-term useb,c
Low intensity 42 352 0.81 (0.58–1.12) 0.81 (0.57–1.14)
Medium intensity 33 273 0.78 (0.54–1.14) 0.86 (0.58–1.26)
High intensity 21 206 0.67 (0.42–1.06) 0.71 (0.44–1.15)
aAdjusted for years of schooling, diabetes, stroke, and use of aspirin, selective cyclooxygenase 2 (Cox2) inhibitors, and non-aspirin-nonsteroidal anti-inflammatory drugs (NA-NSAIDs).
bShort term: o5 years of use; long term: 5þ years of use.
cCutoff values for low-, medium-, and high-intensity statin use defined by tertiles of intensity of use among controls.
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Therefore, lifestyle factors and socioeconomic status are not likely
to have substantially affected our findings.
Because of the observational design of our study, we cannot
exclude the possibility that inadequately measured confounders
influenced our results, although at present only a limited number
of risk factors have been established for glioma (Fisher et al, 2007;
Bondy et al, 2008).
Therefore, our finding of a reduced risk of glioma associated
with long-term statin use may be causal. The possibility of gender-
and age-specific effects, indicated by our study, if replicated in
other settings, could potentially provide guidance to targeted
therapeutic intervention trials.
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APPENDIX
Table A1. List of codes used in the analysis
Cancer codes
Glioma
ICD-10
C71.0-C71.9, C72.0, D33.0-D33.4, D43.0–D43.4
ICD-0-3
94403 – glioblastoma multiforme
94003, 94013, 94103, 94113 – astrocytoma grade II and III
94503, 94513, 94603 – oligodendroglioma grade II and III
93801, 93803, 93813, 93823, 93831, 93900–94001, 94121–94401,
94413–94501 – ‘other’
Anatomical therapeutic classification codes
Statins
C10AA01 – Simvastatin
C10AA02 – Lovastatin
C10AA03 – Pravastatin*
C10AA04 – Fluvastatin
C10AA05 – Atorvastatin
C10AA06 – Cerivastatin
C10AA07 – Rosuvastatin*
Other drugs (covariates)
Antidiabetics
A10A – insulin
A10B – oral antidiabetics
Hormone replacement therapy
G03C, G03D, G03F, G03HB01
Aspirin, low dose (tablet size 75, 100, or 150mg)
B01AC06
Selective Cox-2 inhibitors
M01AH
Non-aspirin NSAIDs
M01A, except M01AH and M01AX
Hospital discharge codes
Diabetes
ICD-8: 249, 250
ICD-10: E10–E14
Stroke
ICD-8: 431, 433, 434
ICD-10: I60, I61, I63
Abbreviations: ICD¼ International Classification of Diseases; Cox-2¼ cyclooxygenase 2;
NSAIDs¼nonsteroidal anti-inflammatory drugs.
*Classified as hydrophilic; other statins classified as lipophilic.
Table A1. (Continued)
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